5HZ5 | pdb_00005hz5

FABP5 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline

• PDB DOI: https://doi.org/10.2210/pdb5HZ5/pdb

• Classification: LIPID BINDING PROTEIN
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2016-02-02 Released: 2017-01-25 
• Deposition Author(s): Ehler, A., Rudolph, M.G.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.40 Å
• R-Value Free: 
  0.228 (Depositor), 0.233 (DCC) 
• R-Value Work: 
  0.208 (Depositor), 0.211 (DCC) 
• R-Value Observed: 
  0.209 (Depositor) 

Literature

Design and synthesis of selective, dual fatty acid binding protein 4 and 5 inhibitors.

Kuhne, H., Obst-Sander, U., Kuhn, B., Conte, A., Ceccarelli, S.M., Neidhart, W., Rudolph, M.G., Ottaviani, G., Gasser, R., So, S.S., Li, S., Zhang, X., Gao, L., Myers, M.

(2016) Bioorg Med Chem Lett 26: 5092-5097

• PubMed: 27658368 
• DOI: https://doi.org/10.1016/j.bmcl.2016.08.071
• Primary Citation Related Structures: 
  5HZ5, 5HZ6, 5HZ8, 5HZ9


• PubMed Abstract: 
  

  Dual inhibition of fatty acid binding proteins 4 and 5 (FABP4 and FABP5) is expected to provide beneficial effects on a number of metabolic parameters such as insulin sensitivity and blood glucose levels and should protect against atherosclerosis. Starting from a FABP4 selective focused screening hit, biostructure information was used to modulate the selectivity profile in the desired way and to design potent dual FABP4/5 inhibitors with good selectivity against FABP3. With very good pharmacokinetic properties and no major safety alerts, compound 12 was identified as a suitable tool compound for further in vivo investigations.

---

Organizational Affiliation: 
• Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland. Electronic address: [e-mail].
Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.
Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, NJ 07110, USA.

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content 

• Total Structure Weight: 15.62 kDa 
• Atom Count: 1,280 
• Modeled Residue Count: 134 
• Deposited Residue Count: 134 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Fatty acid-binding protein, epidermal	A	134	Homo sapiens	Mutation(s): 0  Gene Names: FABP5
UniProt & NIH Common Fund Data Resources
Find proteins for Q01469 (Homo sapiens) Explore Q01469  Go to UniProtKB:  Q01469
PHAROS:  Q01469 GTEx:  ENSG00000164687

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
65X	D [auth A]	6-chloro-4-phenyl-2-(piperidin-1-yl)-3-(1H-tetrazol-5-yl)quinoline C21 H19 Cl N6 FXEKONNOBJEKPB-UHFFFAOYSA-N
SO4	C [auth A]	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L
DMS	B [auth A]	DIMETHYL SULFOXIDE C2 H6 O S IAZDPXIOMUYVGZ-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.40 Å
• R-Value Free:  0.228 (Depositor), 0.233 (DCC) 
• R-Value Work:  0.208 (Depositor), 0.211 (DCC) 
• R-Value Observed: 0.209 (Depositor) 

Space Group: P 4₃ 2₁ 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 62.79	α = 90
b = 62.79	β = 90
c = 75.35	γ = 90

Software Package:

Software Name	Purpose
XSCALE	data scaling
PDB_EXTRACT	data extraction
PHENIX	refinement
XDS	data reduction
REFMAC	phasing

Structure Validation

Entry History 

Deposition Data

• Released Date: 2017-01-25 
Deposition Author(s): Ehler, A., Rudolph, M.G.

Revision History  

• Version 1.0: 2017-01-25
  Type: Initial release
  
• Version 1.1: 2017-10-11
  Changes: Data collection
• Version 1.2: 2024-11-13
  Changes: Data collection, Database references, Structure summary